Advanced or Metastatic Medullary Thyroid Cancer (MTC) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Advanced or Metastatic Medullary Thyroid Cancer (MTC) Market Outlook

Thelansis’s “Advanced or Metastatic Medullary Thyroid Cancer (MTC) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Advanced or Metastatic Medullary Thyroid Cancer treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Advanced or Metastatic Medullary Thyroid Cancer (MTC) Overview

Medullary thyroid cancer originates from the parafollicular cells, also known as C cells, of the thyroid gland, which produces calcitonin. This tumor is derived from neural crest cells and is characterized by elevated calcitonin levels. About 75-80% of medullary thyroid cancers are sporadic, while the remaining cases are familial and occur in multiple endocrine neoplasias (MEN) 2A, MEN 2B, and familial medullary thyroid cancer (FMTC). The development of medullary thyroid cancer can be attributed to RET mutations in the neural crest tissue of the thyroid gland. Germline mutations are associated with MEN2 and FMTC medullary thyroid cancers, while 40-50% of sporadic medullary thyroid cancers have acquired RET mutations. Medullary thyroid cancer associated with multiple MEN syndromes is often multicentric and bilateral, whereas sporadic medullary thyroid cancer is usually unilateral. These tumors typically involve the upper portions of both lobes of the thyroid gland since C cells are predominantly located in the upper poles of the gland. Paraneoplastic syndromes, such as Cushing syndrome and carcinoid syndrome, can also occur in medullary thyroid cancer, producing hormones such as corticotropin, serotonin, prostaglandins, and melanin. The five-year survival rate for stages 1 to 3 of medullary thyroid cancer is 93%, whereas, for stage 4, it is only 28%. Surgical resection is the primary treatment for medullary thyroid carcinoma, as this cancer does not respond to conventional chemotherapy or radioactive iodine (RAI).

• Thyroid cancer represents 2.3% of new malignancies occurring annually in the United States, with an annual incidence of approximately 14.6 per 100,000. Of those thyroid cancer diagnoses, 2% to 3% are medullary thyroid carcinoma (MTC), translating into 1080-1620 new diagnoses annually.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2023-2033

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: